Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of IMO-8400 in Dermatomyositis
2015-003277-15Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- Dec 2015
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dermatomyositis (DM) comparing IMO-8400 with Placebo (2 arms). Primary endpoint: Primary Safety and Tolerability Endpoints. Started Dec 2015; status: completed.
02
Drugs
bazlitoran
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2015-003277-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003277-15.